<li>almotriptan<p>duloxetine, almotriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>aripiprazole<p>duloxetine will increase the level or effect of aripiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>bumetanide<p>bumetanide, duloxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>carvedilol<p>duloxetine will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>celandine<p>celandine decreases effects of duloxetine by pharmacodynamic antagonism. Minor/Significance Unknown. Based on animal studies.</p></li><li>chloroquine<p>chloroquine will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>chlorpromazine<p>duloxetine will increase the level or effect of chlorpromazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>dexfenfluramine<p>duloxetine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>dexmethylphenidate<p>dexmethylphenidate increases effects of duloxetine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>donepezil<p>duloxetine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>doxepin<p>duloxetine will increase the level or effect of doxepin by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>eletriptan<p>duloxetine, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>encainide<p>duloxetine will increase the level or effect of encainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>ethacrynic acid<p>ethacrynic acid, duloxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>ethinylestradiol<p>ethinylestradiol will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.</p></li><li>flecainide<p>duloxetine will increase the level or effect of flecainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>fluoxetine<p>duloxetine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>fluphenazine<p>duloxetine will increase the level or effect of fluphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>fluvoxamine<p>duloxetine will increase the level or effect of fluvoxamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>frovatriptan<p>duloxetine, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>furosemide<p>furosemide, duloxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>galantamine<p>duloxetine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>haloperidol<p>duloxetine will increase the level or effect of haloperidol by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.<span><br><br></span>haloperidol will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>iloperidone<p>duloxetine will increase the level or effect of iloperidone by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>lithium<p>duloxetine, lithium. Mechanism: unknown. Minor/Significance Unknown. Risk of neurotoxicity.</p></li><li>loratadine<p>duloxetine will increase the level or effect of loratadine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>methylphenidate<p>methylphenidate increases effects of duloxetine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>naratriptan<p>duloxetine, naratriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>panax ginseng<p>panax ginseng increases effects of duloxetine by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>paroxetine<p>duloxetine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>perhexiline<p>duloxetine will increase the level or effect of perhexiline by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>perphenazine<p>duloxetine will increase the level or effect of perphenazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>pleurisy root<p>pleurisy root decreases effects of duloxetine by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>prochlorperazine<p>duloxetine will increase the level or effect of prochlorperazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>promazine<p>duloxetine will increase the level or effect of promazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>promethazine<p>duloxetine will increase the level or effect of promethazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>rizatriptan<p>duloxetine, rizatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan<p>duloxetine, sumatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan intranasal<p>duloxetine, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan transdermal<p>duloxetine, sumatriptan transdermal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>tolterodine<p>duloxetine will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>torsemide<p>torsemide, duloxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>trifluoperazine<p>duloxetine will increase the level or effect of trifluoperazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>tropisetron<p>duloxetine will increase the level or effect of tropisetron by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>zolmitriptan<p>duloxetine, zolmitriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li>